Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the 6-month survival rate and safety of talabostat and
gemcitabine in patients with stage IV adenocarcinoma of the pancreas.